Higher dose statins cut MI and deaths, study shows

More intensive cholesterol control could further reduce MI and coronary death, research suggests.

Researchers writing in the Lancet found treatment with higher dose statins led to a 15% reduction in major vascular events.

But a separate study suggested increasing dose of simvastatin from 20mg to 80mg also raises the risk of potentially harmful myopathy.

In the primary study, researchers conducted a meta-analysis of data from 170,000 patients across 26 randomised trials.

They compared both the effect of more and less intensive statin treatment, and the effect of statin treatment versus control.

Researchers found that, across all 26 studies, all-cause mortality was reduced by 10% per 1mmol/L cholesterol reduction

Comparing more and less intensive statin treatment, coronary deaths and non-fatal MI fell 13%; there were 19% fewer surgical procedures for heart disease and the number of strokes fell 16%.

Over five years, intensive cholesterol control would protect an additional four per 100 patients from MI, stroke or related hospital procedure.

But a second study, also published in the Lancet, showed myopathy increased from 0.03% in the simvastatin 20mg group to 0.9% in the simvastatin 80mg group.

Professor Jeremy Pearson, associate medical director at the BHF, warned about simply increasing statin dose in light of increased side-effects.

‘Doctors may wish to consider switching patients to alternative treatments, such as combining statins with other cholesterol-lowering drugs, rather than ramping up the dose,’ he said.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Just published

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

Common conditions in skin of colour

Common conditions in skin of colour

An essential guide to common dermatoses and their presentations in skin of colour.

Common asthma drug speeds up COVID-19 recovery in community for high-risk patients

Common asthma drug speeds up COVID-19 recovery in community for high-risk patients

A common corticosteroid shortens COVID-19 recovery times for patients aged over 50...

Salaried GPs must not be coerced into vaccinating for free, BMA warns

Salaried GPs must not be coerced into vaccinating for free, BMA warns

Salaried GPs should not be coerced into unpaid work for the COVID-19 vaccination...

Delayed risk assessments may have cost BAME doctors' lives, BMA chair warns

Delayed risk assessments may have cost BAME doctors' lives, BMA chair warns

Delayed risk assessments may have contributed to disproportionate deaths among doctors...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...